Market Overview

UPDATE: Deutsche Bank Raises WuXi PharmaTech's PT

Related WX
Jefferies Boosts Targets Across Pharmaceutical Service Stocks
Morgan Stanley Reiterates Overweight, Lowers PT On WuXi PharmaTech On High Near-Term Investment

According to a research report published this morning, Deutsche Bank has increased WuXi PharmaTech's (NYSE: WX) PT from $16 to $17.

In the report, Deutsche Bank said, "WX reported another strong quarter, beating street consensus and guidance on top line and EPS. While management reaffirmed guidance for the full year, we think guidance revision is likely in 3Q12 due to 65% and 109% yoy growth in backlogs for service and manufacturing, respectively. We do not foresee operating leverage in the near term due to RMB appreciation and labour cost inflation."

Deutsche Bank maintains its Buy rating on WuXi PharmaTech, which closed Friday at $14.68.

Latest Ratings for WX

Mar 2015Goldman SachsDowngradesConviction BuyNeutral
Nov 2014JefferiesDowngradesBuyHold
Oct 2013JefferiesMaintainsBuy

View More Analyst Ratings for WX
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings


Related Articles (WX)

Get Benzinga's Newsletters